Xin Lang Cai Jing·2025-10-31 06:30Group 1 - The core point of the news is that CanSino Biologics saw a stock price increase of 5.2%, reaching 79.66 CNY per share, with a trading volume of 207 million CNY and a turnover rate of 2.31%, resulting in a total market capitalization of 19.712 billion CNY [1] - CanSino Biologics, established on January 13, 2009, and listed on August 13, 2020, is located in the Tianjin Economic-Technological Development Area and focuses on the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards [1] - The company's main business revenue composition includes 97.84% from vaccine and related product sales and 2.16% from other supplementary sources [1] Group 2 - From the perspective of fund holdings, one fund under Changxin Fund has a significant position in CanSino, specifically the Changxin Healthcare Mixed (LOF) A fund, which held 35,200 shares in the third quarter, accounting for 2.07% of the fund's net value, ranking as the tenth largest holding [2] - The Changxin Healthcare Mixed (LOF) A fund, established on March 26, 2010, has a latest scale of 128 million CNY and has achieved a year-to-date return of 23.3%, ranking 4079 out of 8154 in its category [2] - The fund manager, Yuan Jie, has been in position for 206 days, with the fund's total asset size at 671 million CNY, achieving a best return of 71.99% and a worst return of -4.9% during her tenure [2]